Malaria Pipeline Landscape Analysis: 15+ Key Players & 20+ Pipeline Drugs

DelveInsight's, "Malaria Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Malaria Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Malaria Pipeline Report
• DelveInsight's Malaria Pipeline analysis depicts a robust space with 15+ active players working to develop 20+ pipeline treatment therapies.
• The leading Malaria Companies such as Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen, and others.
• Promising Malaria Pipeline therapies such as KAE609, Coartem, PfSPZ Vaccine, KAF156, RTS,S/AS01E (SB257049), PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10), and others.
• The companies and academics are working to assess challenges and seek opportunities that could influence Malaria R&D. The therapies under development are focused on novel approaches to treat/improve Malaria.
• This segment of the Malaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Request a sample and discover the recent advances in Malaria Clinical Trials Report @ https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Malaria Overview

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called "malaria vectors." There are 5 parasite species that cause malaria in humans, and 2 of these species - P. falciparum and P. vivax - pose the greatest threat. Malaria is an acute febrile illness. In a non-immune individual, symptoms usually appear 10-15 days after the infective mosquito bite. The first symptoms - fever, headache, and chills - may be mild and difficult to recognize as malaria. If not treated within 24 hours, P. falciparum malaria can progress to severe illness, often leading to death. Early diagnosis and treatment of malaria reduces disease and prevents deaths. Antimalarial medicines can also be used to prevent malaria. For travellers, malaria can be prevented through chemoprophylaxis, which suppresses the blood stage of malaria infections, thereby preventing malaria disease. The most common antimalarial drugs include: Chloroquine phosphate, Chloroquine is the preferred treatment for any parasite that is sensitive to the drug.

Recent Developmental Activities in the Malaria Pipeline Report

Cipargamin is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years. Cipargamin, the first compound in the spiroindolone class of treatment, works through a novel mechanism of action that involves inhibition of a P-type cation-transporter ATPase4 (PfATP4), which regulates sodium concentration in the parasite. Because Cipargamin also appears to be effective against the sexual forms of the parasite, it could potentially help prevent disease transmission. Cipargamin was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections. Currently the product is in Phase II stage of development for the treatment of Malaria.

Malaria Pipeline Therapeutic Assessment

There are approx. 15+ key companies which are developing the therapies for Malaria. The companies which have their Malaria drug candidates in the most advanced stage, i.e. Phase I include Novartis.

Learn more about the emerging Malaria pipeline therapies @ https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Malaria Pipeline Report
• Coverage- Global
• Malaria Therapeutic Assessment by Product Type
• Malaria Therapeutic Assessment by Stage and Product Type
• Malaria Therapeutic Assessment by Route of Administration
• Malaria Therapeutic Assessment by Stage and Route of Administration
• Malaria Therapeutic Assessment by Molecule Type
• Malaria Therapeutic Assessment by Stage and Molecule Type
• Malaria Companies- Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen, and others
• Malaria Pipeline Therapies- KAE609, Coartem, PfSPZ Vaccine, KAF156, RTS,S/AS01E (SB257049), PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10), and others

Table of content
1. Introduction
2. Executive Summary
3. Malaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malaria- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. PfSPZ Vaccine: Sanaria
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cipargamin: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Company name: Drug name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. INE963: Novartis
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Lotilaner: Tarsus Pharmaceuticals
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Malaria Key Companies
24. Malaria Key Products
25. Malaria- Unmet Needs
26. Malaria- Market Drivers and Barriers
27. Malaria- Future Perspectives and Conclusion
28. Malaria Analyst Views
29. Malaria Key Companies
30. Appendix
Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Malaria drugs?
• How many Malaria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Malaria?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malaria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malaria and their status?
• What are the key designations that have been granted to the emerging drugs?

For further information on the Malaria pipeline therapeutics, reach out @ https://www.delveinsight.com/report-store/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.